Treatment of Acute Pyelonephritis in Women with Intramuscular Ceftriaxone: An Out-Patient Study

Abstract

Ceftriaxone, a third-generation cephalosporin with a long half-life, was administered intramuscularly to 30 adult women suffering from acute pyelonephritis. Standard bacteriologic methods were used to identify the pathogens and their susceptibilities before treatment and at intervals during and after treatment. Overall cure was achieved in 25 (85%) of the patients 6 weeks after completion of therapy. The results demonstrate that ceftriaxone is an effective drug when given once a day intramuscularly to out-patients with acute pyelonephritis.

Acute pyelonephritis in pregnancy: A retrospective study

“…Ceftriaxone is the third-generation cephalosporin, and it has a long half-life that permits administration once every 24 h, broad-spectrum coverage against commonly encountered uropathogens and clearly proven effectiveness in the ambulatory treatment of pyelonephritis in non-pregnant subjects. 13,14 Thus, it is rational to start with intravenous ceftriaxone rather than oral nitrofurantoin for treatment of acute antepartum pyelonephritis. It is noteworthy that almost all patients with acute antepartum pyelonephritis in our study were started with intravenous ceftriaxone, before urine culture and sensitivity results were available.…”

Clinical Trial of the Outpatient Management of Pyelonephritis in Pregnancy

“…This third-generation cephalosporin was chosen for its long half-life requiring administration only once every 24 h, its broad-spectrum coverage against common urinary pathogens, and its documented efficacy in the outpatient treatment of pyelonephritis and other serious infections in nonpregnant patients. [2][3][4][5][6] The patient was then seen the following day in the obstetrical clinic at which time 2 g of IM ceftriaxone was administered daily until the resolution of her fever and CVAT, followed by a 10-day course of oral antibiotics based on the culture and sensitivity results. Hospitalization was required for patients who were considered outpatient failures based on persistent fever or CVAT beyond 48 h of parenteral therapy, as well as for patients who developed nausea and vomiting, were noncompliant with clinic visits for parenteral antibiotics, showed evidence of preterm labor, or experienced adverse drug reactions.…”